{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T20:08:59Z","timestamp":1783541339978,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":731,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"XBiotech"}],"content-domain":{"domain":["jvascsurg.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jvs.2015.08.069","type":"journal-article","created":{"date-parts":[[2015,10,2]],"date-time":"2015-10-02T02:01:08Z","timestamp":1443751268000},"page":"133-141.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["A randomized phase II study of Xilonix, a targeted therapy against interleukin 1\u03b1, for the prevention of superficial femoral artery restenosis after percutaneous revascularization"],"prefix":"10.1016","volume":"63","clinical-trial-number":[{"clinical-trial-number":"nct01270945","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hosam","family":"El Sayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kerensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasant","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2015.08.069_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/vhrm.2007.3.2.229","article-title":"Epidemiology, classification, and modifiable risk factors of peripheral arterial disease","volume":"3","author":"Shammas","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jvs.2015.08.069_bib2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jacc.2005.10.009","volume":"47","author":"Hirsch","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2015.08.069_bib3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5114\/aoms.2012.28568","article-title":"Peripheral arterial disease of the lower extremities","volume":"8","author":"Aronow","year":"2012","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jvs.2015.08.069_bib4","first-page":"S1","article-title":"Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC)","volume":"31","author":"Dormandy","year":"2000","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2015.08.069_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1148\/radiology.183.3.1294068","article-title":"Femoral and popliteal arteries: reanalysis of results of balloon angioplasty","volume":"183","author":"Johnston","year":"1992","journal-title":"Radiology"},{"key":"10.1016\/j.jvs.2015.08.069_bib6","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.102.22.2694","article-title":"Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study","volume":"102","author":"Minar","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2015.08.069_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1583\/05-1672.1","article-title":"Long-segment SFA stenting\u2014the dark sides: in-stent restenosis, clinical\u00a0deterioration, and stent fractures","volume":"12","author":"Schlager","year":"2005","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jvs.2015.08.069_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jcin.2013.05.022","article-title":"The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty","volume":"7","author":"Scheinert","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jvs.2015.08.069_bib9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa067193","article-title":"Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents","volume":"356","author":"Stone","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvs.2015.08.069_bib10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa067722","article-title":"Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden","volume":"356","author":"Lagerqvist","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvs.2015.08.069_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbrc.2011.01.008","article-title":"Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1\u03b1","volume":"405","author":"Kamari","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jvs.2015.08.069_bib12","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1161\/01.CIR.0000125700.33637.B1","article-title":"Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors","volume":"109","author":"Waehre","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2015.08.069_bib13","first-page":"951","article-title":"Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis","volume":"138","author":"Moyer","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jvs.2015.08.069_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00401-006-0134-0","article-title":"Expression of \u03b12-macroglobulin, neutrophil elastase, and interleukin-1\u03b1 differs in early-stage and late-stage atherosclerotic lesions in the arteries of the circle of Willis","volume":"113","author":"Larionov","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jvs.2015.08.069_bib15","doi-asserted-by":"crossref","first-page":"H2927","DOI":"10.1152\/ajpheart.00700.2006","article-title":"Endogenous interleukin-1\u03b1 promotes a proliferative and proinflammatory phenotype in human vascular smooth muscle cells","volume":"292","author":"Schultz","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jvs.2015.08.069_bib16","doi-asserted-by":"crossref","first-page":"H901","DOI":"10.1152\/ajpheart.1999.276.3.H901","article-title":"Constitutive expression of interleukin-1\u03b1 precursor promotes human vascular smooth muscle cell proliferation","volume":"276","author":"Beasley","year":"1999","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jvs.2015.08.069_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/cvr\/cvp262","article-title":"A\u00a0novel mouse model of in situ stenting","volume":"85","author":"Chamberlain","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jvs.2015.08.069_bib18","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/01.CIR.0000085567.18648.21","article-title":"Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury","volume":"108","author":"Isoda","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2015.08.069_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cardiores.2005.06.026","article-title":"Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model","volume":"68","author":"Morton","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jvs.2015.08.069_bib20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0161-5890(96)00017-X","article-title":"Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1\u03b1 specific inhibitor","volume":"33","author":"Garrone","year":"1996","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jvs.2015.08.069_bib21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamadermatol.2014.5391","article-title":"Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1\u03b1, for the treatment of psoriasis","volume":"151","author":"Coleman","year":"2015","journal-title":"JAMA Dermatol"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521415018170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521415018170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T20:29:50Z","timestamp":1537302590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521415018170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0741521415018170"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2015.08.069","relation":{},"ISSN":["0741-5214"],"issn-type":[{"value":"0741-5214","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase II study of Xilonix, a targeted therapy against interleukin 1\u03b1, for the prevention of superficial femoral artery restenosis after percutaneous revascularization","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2015.08.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}